The reovirus fusion-associated small transmembrane (FAST) proteins are the smallest known viral membrane-fusion proteins. How these diminutive fusogens mediate cell-cell fusion and syncytium formation is unclear. Ongoing efforts are aimed at defining the roles of the FAST protein ecto-, endo- and transmembrane domains in the membrane-fusion reaction. We now provide direct evidence for homomultimer formation by the FAST proteins by using an anti-haemagglutinin (HA) mAb to co-precipitate the untagged p14 FAST protein from cells co-transfected with HA-tagged p14. Disrupting the intracellular endoplasmic reticulum-Golgi complex vesicle transport pathway prevented p14 homomultimer formation, while lower pH disrupted p14 multimers. The p14 endodomain or transmembrane domains are not required for multimer formation, which, along with the pH sensitivity and the distribution of histidine residues, suggests the 36 aa p14 ectodomain is a multimerization motif.

Download full-text PDF

Source
http://dx.doi.org/10.1099/vir.0.026013-0DOI Listing

Publication Analysis

Top Keywords

fusion-associated small
8
small transmembrane
8
fast proteins
8
fast protein
8
transmembrane domains
8
homomultimer formation
8
p14
7
homomultimerization reovirus
4
reovirus p14
4
p14 fusion-associated
4

Similar Publications

Ribosome biogenesis plays a pivotal role in maintaining stem cell homeostasis, yet the precise regulatory mechanisms governing this process in mouse embryonic stem cells (mESCs) remain largely unknown. In this investigation, we ascertain that DEAD-box RNA helicase 10 (DDX10) is indispensable for upholding cellular homeostasis and the viability of mESCs. Positioned predominantly at the nucleolar dense fibrillar component (DFC) and granular component (GC), DDX10 predominantly binds to 45S ribosomal RNA (rRNA) and orchestrates ribosome biogenesis.

View Article and Find Full Text PDF

Human adenovirus (HAdV)-based oncolytic vectors, which are designed to preferentially replicate in and kill cancer cells, have shown modest efficacy in human clinical trials in part due to poor viral distribution throughout the tumor mass. Previously, we showed that expression of the p14 fusion-associated small transmembrane (FAST) fusogenic protein could enhance oncolytic HAdV efficacy and reduce tumor growth rate in a human xenograft mouse model of cancer. We now explore whether co-expression of the adenovirus death protein (ADP) with p14 FAST protein could synergize to further enhance oncolytic vector efficacy.

View Article and Find Full Text PDF

Avian deltacoronaviruses encode fusion-associated small transmembrane proteins that can induce syncytia formation.

Virology

December 2024

Department of Pediatrics, Vanderbilt University Medical Center, 2200 Children's Way, Suite 2404, Nashville, TN, 37232, USA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Medical Center North, 1161 21st Ave. South, Suite D-2220, Nashville, TN, 37232, USA. Electronic address:

Fusion-associated small transmembrane (FAST) proteins are nonstructural viral proteins that induce cell-cell fusion. FAST proteins, which previously were identified in the genomes of double-stranded RNA viruses, typically contain an acylated N-terminal ectodomain, central transmembrane domain, and C-terminal endodomain with a polybasic region. Using sequence homology and protein motif prediction, we identified accessory proteins in a subset of avian deltacoronaviruses as putative FAST proteins.

View Article and Find Full Text PDF

Purpose: DEK::AFF2 fusion-associated squamous cell carcinoma (DEK::AFF2 SCC), also reported in the literature as low-grade papillary sinonasal (Schneiderian) carcinoma (LGPSC), is a rare, primarily bland-appearing, but locally aggressive neoplasm. Morphologically, these tumors can closely resemble sinonasal papilloma (SP), especially on small or limited biopsy, often leading to misdiagnosis. DEK::AFF2 SCC is devoid of the underlying mutually exclusive EGFR or KRAS driver mutations of SP, suggesting it may represent a distinct unique entity.

View Article and Find Full Text PDF

Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles.

Cell

September 2024

Department of Oncology, University of Alberta, Edmonton, AB T6G 2E1, Canada; Entos Pharmaceuticals, 10230 Jasper Avenue, Suite 4550, Edmonton, AB T5J 4P6, Canada; OncoSenX, 701 Fifth Avenue, Suite 4200, Seattle, WA 98104, USA; Oisin Biotechnologies, 701 Fifth Avenue, Suite 4200, Seattle, WA 98104, USA. Electronic address:

Genetic medicines show promise for treating various diseases, yet clinical success has been limited by tolerability, scalability, and immunogenicity issues of current delivery platforms. To overcome these, we developed a proteolipid vehicle (PLV) by combining features from viral and non-viral approaches. PLVs incorporate fusion-associated small transmembrane (FAST) proteins isolated from fusogenic orthoreoviruses into a well-tolerated lipid formulation, using scalable microfluidic mixing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!